HuGE Literature Finder
Records 1-13
|
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Leukemia research 2019 Apr 81 75-81. Spunarova Michaela, Tom Nikola, Pavlova Sarka, Mraz Marek, Brychtova Yvona, Doubek Michael, Panovska Anna, Skuhrova Francova Hana, Brzobohata Anna, Pospisilova Sarka, Mayer Jiri, Trbusek Mart |
|
Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.
Genes, chromosomes & cancer 2018 Sep . Roos-Weil Damien, Nguyen-Khac Florence, Chevret Sylvie, Touzeau Cyrille, Roux Clémence, Lejeune Julie, Cosson Adrien, Mathis Stéphanie, Feugier Pierre, Leprêtre Stéphane, Béné Marie-Christine, Baron Marine, Raynaud Sophie, Struski Stéphanie, Eclache Virginie, Sutton Laurent, Lesty Claude, Merle-Béral Hélène, Cymbalista Florence, Ysebaert Loïc, Davi Frédéric, Leblond Véronique, |
|
A polymorphism (rs1042522) in TP53 gene is a risk factor for Down Syndrome in Sicilian mothers.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2016 Dec 1-3. Salemi Michele, Barone Concetta, Salluzzo Maria Grazia, Giambirtone Mariaconcetta, Scillato Francesco, Galati Rando Rosanna, Romano Carmelo, Morale Maria Concetta, Ridolfo Federico, Romano Corra |
|
Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Hematological oncology 2016 Sep . Le Bris Yannick, Struski Stéphanie, Guièze Romain, Rouvellat Caroline, Prade Naïs, Troussard Xavier, Tournilhac Olivier, Béné Marie C, Delabesse Eric, Ysebaert Lo |
|
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Leukemia 2015 Feb 29 (2): 329-36. Baliakas P, Hadzidimitriou A, Sutton L-A, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli M J J, Smedby K E, Juliusson G, Anagnostopoulos A, Makris A M, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford J C, Stamatopoulos K, Rosenquist R, |
|
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Leukemia & lymphoma 2014 Dec 55 (12): 2785-92. Chiaretti Sabina, Marinelli Marilisa, Del Giudice Ilaria, Bonina Silvia, Piciocchi Alfonso, Messina Monica, Vignetti Marco, Rossi Davide, Di Maio Valeria, Mauro Francesca Romana, Guarini Anna, Gaidano Gianluca, Foà Rob |
|
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.
Hematological oncology 2014 Mar 32 (1): 22-30. Falisi Erika, Novella Elisabetta, Visco Carlo, Guercini Nicola, Maura Francesco, Giaretta Ilaria, Pomponi Fabrizio, Nichele Ilaria, Finotto Silvia, Montaldi Annamaria, Neri Antonino, Rodeghiero Frances |
|
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
Leukemia 2014 Jan 28 (1): 108-17. Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A, Haferlach T, Kern W, Schnittger |
|
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Blood 2013 Jan 121 (3): 468-75. Oscier David G, Rose-Zerilli Matthew J J, Winkelmann Nils, Gonzalez de Castro David, Gomez Belen, Forster Jade, Parker Helen, Parker Anton, Gardiner Anne, Collins Andrew, Else Monica, Cross Nicholas C P, Catovsky Daniel, Strefford Jonathan |
|
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.
Haematologica 2012 Mar 97 (3): 437-41. Del Giudice Ilaria, Rossi Davide, Chiaretti Sabina, Marinelli Marilisa, Tavolaro Simona, Gabrielli Sara, Laurenti Luca, Marasca Roberto, Rasi Silvia, Fangazio Marco, Guarini Anna, Gaidano Gianluca, Foà Rob |
|
Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia.
Leukemia & lymphoma 2011 Jun 52 (6): 1055-65. Pileckyte Regina, Jurgutis Mindaugas, Valceckiene Vilma, Stoskus Mindaugas, Gineikiene Egle, Sejoniene Jurgita, Degulys Andrius, Zvirblis Tadas, Griskevicius Laimon |
|
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Neuro-oncology 2011 Feb 13 (2): 235-41. Taal Walter, Dubbink Hendrikus J, Zonnenberg Chris B L, Zonnenberg Bernard A, Postma Tjeerd J, Gijtenbeek Johanna M M, Boogerd Willem, Groenendijk Floris H, Kros Johan M, Kouwenhoven Mathilde C M, van Marion Ronald, van Heuvel Irene, van der Holt Bronno, Bromberg Jacoline E C, Sillevis Smitt Peter A E, Dinjens Winand N M, van den Bent Martin J, |
|
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.
Leukemia 2010 Dec 24 (12): 2072-9. Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Häbe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Döhner H, Stilgenbauer S, |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: